Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Efficacy of Macrolide Immunomodulation in Severe Sepsis.
This study is currently recruiting participants.
Verified by Department of Veterans Affairs, December 2008
Sponsors and Collaborators: Department of Veterans Affairs
University Hospital
Feinberg School of Medicine, Northwestern University
Information provided by: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00708799
  Purpose

The purpose of this study is to determine whether macrolide treatment of patients with severe sepsis has an advantageous immunomodulatory and clinical effect compared to severe septic patients without macrolide therapy. Our main hypothesis is macrolide use in addition to standard therapy in severe septic patients has an advantageous immunomodulatory and clinical effect compared to patients with severe sepsis not treated with a macrolide.


Condition Intervention Phase
Systemic Inflammatory Response Syndrome
Other: Azithromycin on admission - not enrolled in the RCT
Phase II

MedlinePlus related topics: Sepsis
Drug Information available for: Azithromycin
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Efficacy of Macrolide Immunomodulation in Severe Sepsis

Further study details as provided by Department of Veterans Affairs:

Primary Outcome Measures:
  • Change in cytokines expression [ Time Frame: Between admission and day five of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • 28-day mortality [ Time Frame: 28 days or discharge ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 100
Study Start Date: November 2007
Estimated Study Completion Date: November 2010
Estimated Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
Standard antibiotic therapy +Azithromycin 500 mg intravenously daily for 5 days
Other: Azithromycin on admission - not enrolled in the RCT
One dose of azithromycin prior to inclusion to the RCT
2: No Intervention
Standard antibiotic therapy

Detailed Description:

In recent studies, the significant effects of macrolide antibiotics (azithromycin) on immune response, unrelated to their anti-microbial properties, have been appreciated. . Clinical trials of macrolides added to -lactams in bacteremic Streptococcus pneumoniae community-acquired pneumonia (CAP) have consistently demonstrated an absolute risk reduction in mortality of 15% in most populations. Several cytokines including tumor necrosis factor (TNF ) interleukin (IL) -1 and IL-8 which are generally proinflammatory and IL-6 and IL-10, which tend to be anti-inflammatory have been associated with sepsis. TNF is a cytokine that for a number of reasons is thought to play a central role in the pathogenesis of sepsis and septic shock.TNF concentrations are increased during clinical and experimental sepsis and increasing concentrations and especially persistence of high concentrations of TNF during sepsis are associated with decreased survival.Therefore, our primary aim is to determine whether macrolide treatment of patients with severe sepsis has an advantageous immunomodulatory and clinical effect compared to severe septic patients without macrolide therapy. Our main hypothesis is macrolide use in addition to standard therapy in severe septic patients has an advantageous immunomodulatory and clinical effect compared to patients with severe sepsis not treated with a macrolide.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

1.Subject, or legal representative, has given written informed consent.

2.18 years of age or older.

3.SIRS is defined as two or more of:

  • Temperature > 38o C or < 36oC
  • Heart rate > 90 beats/min
  • Respiratory rate > 20 breaths/min or PaCO2< 32mmHg
  • White blood cell count > 12.000/mm3; < 4000/mm3; or > 10% immature (band) forms.

    4.Presence of a suspected or proven infection. Patients with suspected infection must have evidence of an infection, such as white blood cells in a normally sterile body fluid, perforated viscus, chest x-ray consistent with pneumonia and associated with purulent sputum production, or a clinical syndrome associated with a high probability of infection (for example, purpura fulminans or ascending cholangitis).

    5.Presence of one or more sepsis-associated organ failure. The onset of the first sepsis-associated organ failure must occur within the 48-hour period immediately preceding initiation of study drug infusion. A patient must have an organ failure attributable to the sepsis episode. The organ failure must be newly developed and not explained by underlying disease processes or by effects of concomitant therapy.

  • Cardiovascular: An arterial systolic blood pressure (SBP) of 90 mm Hg or a mean arterial pressure (MAP) 70 mm Hg for at least 1 hour despite adequate fluid resuscitation, adequate intravascular volume status, or the need for vasopressors to maintain SBP 90 mm Hg or MAP 70 mm Hg.
  • Renal: Average urine output <0.5 mL/kg/h for 1 hour despite adequate fluid resuscitation
  • Respiratory: Evidence of acute pulmonary dysfunction PaO2/FiO2 300 and, clinical exam or pulmonary capillary wedge pressure not suggestive of volume overload. If pneumonia is the suspected site of infection, the patient must have a PaO2/FiO2 200.
  • Hematology: Platelet count <80,000/mm3 or a 50% decrease in platelet count from the highest value recorded over the last 3 days.
  • Unexplained metabolic acidosis: Defined by (1) pH 7.30 or base deficit 5.0 mEq/L or (2) plasma lactate level >1.5 times the upper limit of normal.

Adequate fluid resuscitation or adequate intravascular volume is defined as either pulmonary arterial wedge pressure 12 mm Hg or central venous pressure 8 mm Hg. Vasopressors is defined as dopamine 5 g/kg/min or any dose of norepinephrine, epinephrine, or phenylephrine. Dobutamine is not considered a vasopressor.

Exclusion Criteria:

  1. Macrolide therapy indicated for clinical condition. If after randomization, the treating physician determines that a macrolide is indicated and no other alternative antibiotic is appropriate, the patient will be excluded from the trial. However, if only one dose of azithromycin had been given and the treating physician decided to stop it, azithromycin might be administered.
  2. Known allergy to macrolides.
  3. Prolonged QT syndrome or on medications with increased risk of QT prolongation.
  4. Pregnant or lactating.

Immunosuppression as defined by:

  1. Chemotherapy within the last 30 days,
  2. Leukemia or lymphoma which is not in remission,
  3. Solid organ or bone marrow/stem cell transplant,
  4. Human Immunodeficiency Virus infection with CD4 count < 200 cells/mm3,
  5. Chronic corticosteroid use equivalent to > 10 mg prednisone per day,
  6. Patient or family decision to limit ICU care.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00708799

Contacts
Contact: Maria I Velez, MD (210) 913-0828 maria.velez@va.gov
Contact: Timothy Houlihan, RN (210) 807-0674 ext 14549 houlihan@uthscsa.edu

Locations
United States, Texas
VA South Texas Health Care System Recruiting
San Antonio, Texas, United States, 78229
Contact: Maria I Velez, MD     210-913-0828     maria.velez@va.gov    
Contact: Marcos I Restrepo, MD BA     (210) 815-7511 ext 15443     marcos.restrepo@va.gov    
Principal Investigator: Marcos I. Restrepo, MD BA            
Sponsors and Collaborators
University Hospital
Feinberg School of Medicine, Northwestern University
Investigators
Principal Investigator: Marcos I. Restrepo, MD BA VA South Texas Health Care System
  More Information

Responsible Party: Department of Veterans Affairs ( Restrepo, Marcos - Principal Investigator )
Study ID Numbers: VISN 17-001, UHS#20151
Study First Received: June 27, 2008
Last Updated: December 22, 2008
ClinicalTrials.gov Identifier: NCT00708799  
Health Authority: United States: Federal Government

Study placed in the following topic categories:
Systemic Inflammatory Response Syndrome
Sepsis
Shock
Azithromycin
Inflammation

Additional relevant MeSH terms:
Anti-Infective Agents
Anti-Bacterial Agents
Pathologic Processes
Disease
Therapeutic Uses
Syndrome
Infection
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009